North America continues to be the primary engine of growth for the cardiovascular diagnostics sector, specifically in the identification of asymptomatic or "silent" myocardial infarctions. As the region with the highest healthcare expenditure and a robust network of research institutions, North America is at the forefront of transitioning silent heart attack detection from reactive treatment to proactive, data-driven prevention. By 2031, the regional market is expected to solidify its dominance, driven by an aging population, high rates of metabolic disorders, and a rapid shift toward decentralized cardiac monitoring.
The North American silent heart attack market is projected to reach a significant valuation by 2031, maintaining a strong position within the global industry. In 2024, the region held a dominant market share of approximately 43.4%, with a market value estimated at US$ 11.2 billion. This growth is supported by a steady Compound Annual Growth Rate (CAGR) as the "silent heart attack" sector evolves to incorporate more sophisticated screening tools. The U.S. remains the largest contributor to this regional revenue, fueled by the fact that nearly one in five heart attacks in the United States is silent, necessitating widespread adoption of high-sensitivity diagnostic technologies.
Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00007615
Key Drivers of Growth in North America
The expansion of the silent heart attack market in North America is propelled by several distinct regional factors:
- High Prevalence of Risk Factors and Diabetic Neuropathy
North America faces some of the world's highest rates of obesity and Type 2 diabetes. Patients with diabetes are at an elevated risk for silent heart attacks due to nerve damage (neuropathy) that can mask the typical pain of a cardiac event. As the prevalence of metabolic syndrome increases, healthcare providers are mandating more frequent cardiac screenings for these populations, utilizing high-sensitivity troponin tests to detect subclinical heart damage.
- Rapid Adoption of Digital Health and Wearable Monitoring
The North American digital health market for cardiovascular care is witnessing explosive growth, with a projected CAGR of 21.3% through 2031. Consumers in the U.S. and Canada are early adopters of smartwatches and portable ECG monitors equipped with AI algorithms. These devices allow for continuous, real-time monitoring of heart rhythms and ischemia markers, enabling the detection of "silent" events that would traditionally go unnoticed between annual check-ups.
- Advanced Diagnostic Infrastructure and Clinical Guidelines
North America possesses a highly developed infrastructure of specialized cardiac care units and diagnostic centers. The American College of Cardiology (ACC) and American Heart Association (AHA) have established rigorous guidelines that encourage the use of high-sensitivity biomarkers and non-invasive imaging. This clinical environment ensures that new technologies—such as AI-driven cardiac CT analysis—are rapidly integrated into standard hospital workflows.
- Increasing Geriatric Population and Preventive Health Spending
With approximately 17% of the U.S. population aged 65 and older, there is a massive demographic shift toward age-related cardiovascular risk management. Increased government and private healthcare spending are being directed toward preventive screenings for seniors. This shift is driving the demand for ambulatory cardiac monitors and point-of-care testing kits in primary care settings, moving the point of diagnosis closer to the patient.
Top Key Players in the North American Ecosystem
The competitive landscape in North America features a mix of global med-tech leaders and specialized diagnostic innovators:
- Abbott Laboratories (U.S.-based leader in high-sensitivity troponin assays and insertable monitors)
- GE Healthcare (Providing gold-standard cardiac imaging and ECG technology)
- Boston Scientific Corporation (Innovators in ambulatory cardiac monitoring and interventional diagnostics)
- Roche Diagnostics USA (A primary provider of cardiac biomarker testing platforms)
- Siemens Healthineers (Leading the transition to AI-integrated cardiac imaging)
- Philips Healthcare (Focused on remote cardiac diagnostics and patient monitoring)
- Baxter International (Hill-Rom) (Providing specialized ECG and monitoring solutions)
- iRhythm Technologies, Inc. (Specializing in long-term ambulatory cardiac monitoring)
Related Reports @
Anesthesia Gas Evaporators Market Analysis and Forecast by Size, Share, Growth, Trends 2031
Veterinary Surgical Procedures Market Growth, Key Players, and Forecast by 2031
About Us -
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Information
Email: sales@theinsightpartners.com